<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03477487</url>
  </required_header>
  <id_info>
    <org_study_id>XT-150-1-0202</org_study_id>
    <nct_id>NCT03477487</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain</brief_title>
  <official_title>Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xalud Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xalud Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of Safety, Tolerability, and Efficacy of XT-150, a plasmid DNA with a variant of&#xD;
      human IL-10 transgene. XT-150 will be a single injection into the knee synovial capsule for&#xD;
      the Treatment of Osteoarthritic Pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 dose escalation study to evaluate the safety, tolerability, and efficacy of a plasmid&#xD;
      DNA encoding a variant of human IL-10. This 6-month study will follow subjects with severe&#xD;
      osteoarthritis of the knee. Safety labs, physical exams, and blood levels of the IL-10&#xD;
      variant will be assessed for tolerability and any adverse events associated with the&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2018</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">July 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Ascending dose-ranging study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical, laboratory measures of safety by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale of Pain Intensity</measure>
    <time_frame>6 months</time_frame>
    <description>Validated index of pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcomes Scale</measure>
    <time_frame>6 months</time_frame>
    <description>KOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC</measure>
    <time_frame>6 Months</time_frame>
    <description>Western Ontario and McMasters University Osteoarthritis Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>6 months</time_frame>
    <description>Measure of pain associated with osteoarthritis</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Lowest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The lowest dose of XT-150 in the escalation schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 2nd dose of XT-150 in the escalation sequence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Third dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 3rd dose of XT-150 in the escalation sequence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The highest dose of XT-150 in the escalation sequence</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XT-150</intervention_name>
    <description>Human IL-10 variant transgene in a plasmid DNA vector</description>
    <arm_group_label>Highest dose</arm_group_label>
    <arm_group_label>Lowest dose</arm_group_label>
    <arm_group_label>Second dose</arm_group_label>
    <arm_group_label>Third dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, between 18 and 90 years of age, inclusive&#xD;
&#xD;
          2. Sufficiently severe OA of the knee to meet accepted criteria for knee arthroplasty&#xD;
&#xD;
          3. Free of intra-articular infection, or infection at the injection site.&#xD;
&#xD;
          4. Symptomatic disease because of osteoarthritis, defined as one or more of the following&#xD;
             Visual Analog Scale of Pain Intensity (VASPI) scores:&#xD;
&#xD;
               1. a worst pain of at least 70 at any time during the preceding week (based on scale&#xD;
                  of 0 to 100, with 100 representing &quot;pain as bad as you can imagine&quot;).&#xD;
&#xD;
               2. a worst stiffness of at least 70 at any time during the preceding week (based on&#xD;
                  a scale of 0 to 100, with 100 representing &quot;stiffness as bad as you can&#xD;
                  imagine&quot;).&#xD;
&#xD;
          5. Stable analgesic regimen during the 4 weeks prior to enrollment.&#xD;
&#xD;
          6. Inadequate pain relief (minimum ≥5 mean on the Brief Pain Inventory-Severity Scale)&#xD;
             lasting ≥3 months.&#xD;
&#xD;
          7. In the judgment of the Investigator, acceptable general medical condition&#xD;
&#xD;
          8. Life expectancy &gt;6 months&#xD;
&#xD;
          9. Female subjects of child-bearing potential, and those &lt;1 year post-menopausal, must be&#xD;
             practicing effective methods of birth control such as hormonal methods (e.g., combined&#xD;
             oral, implantable, injectable, or transdermal contraceptives), double barrier methods&#xD;
             (e.g., condoms, sponge, diaphragm) or total abstinence from heterosexual intercourse&#xD;
             for a minimum of 1 month before study drug administration and agree to continue&#xD;
             prevention methods for 3 months after participation in the study is completed.&#xD;
&#xD;
         10. Male subjects who are heterosexually active and not surgically sterile must agree to&#xD;
             use effective contraception, including abstinence, for the duration of the study and&#xD;
             for 3 months after the study is completed.&#xD;
&#xD;
         11. Have suitable knee joint anatomy for intra-articular injection&#xD;
&#xD;
         12. Willing and able to return for the follow-up (FU) visits&#xD;
&#xD;
         13. Able to reliably provide pain assessment&#xD;
&#xD;
         14. Able to read and understand study instructions, and willing and able to comply with&#xD;
             all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. 1. Hypersensitivity, allergy, or significant reaction to any ingredient of the study&#xD;
             drug, including double-stranded DNA, mannose, and sucrose&#xD;
&#xD;
          2. Subject plans knee arthroplasty within 4 months, irrespective of the outcome of the&#xD;
             trial or other conservative therapies&#xD;
&#xD;
          3. High peri-procedural risks which in the judgment of the investigator preclude a safe&#xD;
             knee injection procedure (e.g., poorly controlled diabetes, cardiac inadequacy such as&#xD;
             NYHA class &gt; II, G4 glomerular filtration rate [eGFR &lt; 30 mL/min by Cockcroft-Gault])&#xD;
&#xD;
          4. Current treatment with immunosuppressives (steroid therapy equivalent to &gt;10mg/day&#xD;
             prednisone); or other strong immunosuppressant&#xD;
&#xD;
          5. History of systemic immunosuppressive therapy; steroids (equivalent to &gt;10mg/day&#xD;
             prednisone) in the last 3 months&#xD;
&#xD;
          6. Currently receiving systemic chemotherapy or radiation therapy for malignancy&#xD;
&#xD;
          7. Clinically significant hepatic disease as indicated by clinical laboratory results ≥3&#xD;
             times the upper limit of normal for any liver function test (e.g., aspartate&#xD;
             aminotransferase, alanine aminotransferase, lactate dehydrogenase)&#xD;
&#xD;
          8. Severe anemia (Grade 3; hemoglobin &lt;8.0 g/dL, &lt;4.9 mmol/L, &lt;80 g/L; transfusion&#xD;
             indicated), uncontrolled coagulopathy (Grade 1, prolonged activated partial&#xD;
             prothrombin time (aPTT) &gt; upper limit of normal (ULN) to 1.5xULN), or bleeding&#xD;
             diathesis, Grade 1 white cell counts (lymphocytes &lt;LLN - 800/mm3; &lt;LLN - 0.8 x 10e9&#xD;
             /L, neutrophils &lt;LLN - 1500/mm3; &lt;LLN - 1.5 x 10e9 /L)&#xD;
&#xD;
          9. Positive serology for human immunodeficiency virus, hepatitis B virus, or hepatitis C&#xD;
             virus within 4 weeks of commencing the study&#xD;
&#xD;
         10. Significant neuropsychiatric conditions; dementia, major depression, or altered mental&#xD;
             state that in the opinion of the Investigator will interfere with study participation&#xD;
&#xD;
         11. Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical&#xD;
             treatments)&#xD;
&#xD;
         12. Current treatment with anticoagulants, other than low-dose aspirin, prescribed for new&#xD;
             onset of symptoms in 3 months before screening visit.&#xD;
&#xD;
         13. Known or suspected history of active alcohol or intravenous/oral drug abuse within 1&#xD;
             year before the screening visit&#xD;
&#xD;
         14. Women who are pregnant or nursing&#xD;
&#xD;
         15. Use of any investigational drug or device within 1 month before enrollment or current&#xD;
             participation in a trial that included intervention with a drug or device; or&#xD;
             currently participating in an investigational drug or device study.&#xD;
&#xD;
         16. Any condition that, in the opinion of the Principal Investigator, could compromise the&#xD;
             safety of the subject, the subject's ability to communicate with the study staff, or&#xD;
             the quality of the data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Collins, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Xalud Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurovations (Napa Pain Institute)</name>
      <address>
        <city>Napa</city>
        <state>California</state>
        <zip>94558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2018</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Interleukin-10</keyword>
  <keyword>Gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

